BioNTech, Bristol Myers Squibb report 36.7% response rate for pumitamig combination in Phase 2 lung cancer trial
BNTX•BioNTech and Bristol Myers Squibb reported a 36.7% response rate for investigational pumitamig combined with docetaxel in a Phase 2 trial of previously treated metastatic non-small cell lung cancer.
1. Phase 2 results
The combination showed tumor responses across cancer subtypes and PD-L1 expression levels in patients whose disease progressed following immunotherapy with chemotherapy. The companies said safety was manageable, with no new safety signals or pumitamig-related deaths. Results were presented at the European Society for Medical Oncology Congress in Madrid on October 25, 2026, and will inform further development in second-line lung cancer; the program has four ongoing global Phase 3 trials.
